A Drug Designed Entirely by AI Reaches Its Final Round of Human Testing
Insilico Medicine's rentosertib, a lung disease drug whose target and molecule were both discovered by generative AI, has entered Phase III trials after showing measurable lung-function gains in an earlier study.